PriceTargets.com logo

Osmotica Pharmaceuticals - OSMT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/31/1969 06:45 PM ET
+0 (0.00%)
Get New Osmotica Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSMT

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Osmotica Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for OSMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Osmotica Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/23/2021HC WainwrightInitiated CoverageBuy$5.00High
11/9/2021Jefferies Financial GroupInitiated CoverageBuyHigh
10/11/2021Truist FinancialLower TargetBuy$7.00 ➝ $5.00Low
9/24/2021Cantor FitzgeraldInitiated CoverageOverweight$6.00High
4/2/2021Royal Bank of CanadaReiterated RatingBuyN/A
3/17/2021Royal Bank of CanadaLower TargetOutperform$12.00 ➝ $8.00Low
12/30/2020Truist FinancialLower Target$11.00 ➝ $8.00N/A
9/3/2020Wells Fargo & CompanyReiterated RatingHoldHigh
7/10/2020SunTrust BanksBoost TargetBuy$8.00 ➝ $11.00High
7/10/2020SVB LeerinkBoost TargetOutperform$8.00 ➝ $10.00High
7/9/2020Royal Bank of CanadaBoost Target$10.00 ➝ $12.00High
3/25/2020Royal Bank of CanadaReiterated RatingBuy$10.00High
3/23/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$4.00Low
3/18/2020SunTrust BanksInitiated CoverageBuy$8.00High
3/6/2020SVB LeerinkInitiated CoverageOutperform$10.00Low
8/12/2019Jefferies Financial GroupSet TargetBuy$10.00Medium
8/9/2019Wells Fargo & CompanyReiterated RatingBuyLow
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$11.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Osmotica Pharmaceuticals logo
Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.16
Low: $0.98
High: $1.49

52 Week Range

Now: N/A

Volume

296,500 shs

Average Volume

396,682 shs

Market Capitalization

$69.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Osmotica Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Osmotica Pharmaceuticals in the last twelve months:
View the latest analyst ratings for OSMT.

What is the current price target for Osmotica Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Osmotica Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Osmotica Pharmaceuticals in the next year.
View the latest price targets for OSMT.

What is the current consensus analyst rating for Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OSMT.

What other companies compete with Osmotica Pharmaceuticals?

Other companies that are similar to Osmotica Pharmaceuticals include Anebulo Pharmaceuticals, Landos Biopharma, Journey Medical, Carisma Therapeutics and Viveon Health Acquisition. Learn More about companies similar to Osmotica Pharmaceuticals.

How do I contact Osmotica Pharmaceuticals' investor relations team?

Osmotica Pharmaceuticals' physical mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company's listed phone number is (908) 809-1300 and its investor relations email address is [email protected]. The official website for Osmotica Pharmaceuticals is www.osmotica.com. Learn More about contacing Osmotica Pharmaceuticals investor relations.